Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Capecitabine vs Platinum and Etoposide in Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
NCT02595424Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Nov 2015
- Primary completion
- Apr 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, capecitabine in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by ECOG-ACRIN Cancer Research Group. Started Nov 2015; status: active, not recruiting.
02
Drugs
temozolomidecapecitabine
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT02595424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595424.